Pharmaceutical Commerce
AUGUST 8, 2024
In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.
Fierce Pharma
AUGUST 5, 2024
The family of a Baltimore woman whose cells were extracted for medical research without her consent more than 70 years ago has filed another lawsuit against drugmakers that allegedly profited from | The family of a Baltimore woman whose cells were extracted for medical research without her consent more than 70 years ago has filed another lawsuit against drugmakers that allegedly profited from the discoveries they made using her genetic material.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
AUGUST 8, 2024
More than 700 hospitals across the rural U.S. are at risk of closing due to their financial woes — and for more than half of these hospitals, the risk of closure is immediate, according to a new report. The report argued this is due largely to inadequate reimbursement from health plans. The post Why More Than 30% of Rural Hospitals Are at Risk of Closure appeared first on MedCity News.
pharmaphorum
AUGUST 9, 2024
Eli Lilly's oral tau drug fails to show efficacy in a phase 2 trial in Alzheimer's disease in another setback for the class
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
PharmaTimes
AUGUST 8, 2024
The study predicted the development of conditions including Alzheimer’s and heart disease
Fierce Pharma
AUGUST 5, 2024
While Pfizer’s German mRNA partner BioNTech has high hopes for its post-COVID future, the company continues to feel the squeeze from the changeover to a seasonal vaccine market. | While Pfizer’s German mRNA partner BioNTech has high hopes for its post-COVID future, the company continues to feel the squeeze from the changeover to a seasonal vaccine market.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
AUGUST 8, 2024
Recursion Pharma has agreed to merge with rival AI-powered drug discovery firm Exscientia in an all-stock deal valued at $688 million
PharmaTimes
AUGUST 9, 2024
The study revealed that 13% of patients have a genetic form of the neurological disease
Fierce Pharma
AUGUST 8, 2024
Following the commercial launch of Bavarian Nordic’s smallpox/mpox vaccine Jynneos earlier this year, the Danish company has locked up yet another supply agreement with the U.S. government. | The Biomedical Advanced Research and Development Authority (BARDA) is handing Bavarian Nordic $156.8 million to “partly replenish” Jynneos vaccine stocks in response to the 2022 outbreak of mpox, the disease formerly known as monkeypox.
MedCity News
AUGUST 9, 2024
The White House might soon finalize a rule that will either save or cost patients billions of dollars in prescription drug costs. The rule concerns “copay accumulators,” which are programs health plans use to prevent copay assistance from counting toward patients’ deductibles or out-of-pocket maximums. The post An Upcoming White House Decision May Jeopardize Americans’ Access to Life-Saving Drugs appeared first on MedCity News.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
AUGUST 7, 2024
BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian but is reining back its ambitions for the business, for now
PharmaTimes
AUGUST 9, 2024
In the UK, there are an estimated 11 million people living with a neurological condition
Fierce Pharma
AUGUST 6, 2024
Warning of a "silent pandemic" spreading across the globe, Pfizer is taking the fight against antimicrobial resistance (AMR) Down Under. | Pfizer announced Tuesday that it has invested 150 million Australian dollars (about $98 million) to build a new manufacturing facility at its Australian site in Melbourne, where the company will help produce new antimicrobial treatments aimed at addressing the rising tide of antimicrobial resistance.
MedCity News
AUGUST 6, 2024
The FDA approved Servier Pharmaceuticals’ Voranigo as a treatment for two types of low-grade gliomas. The drug, which is projected to become a blockbuster product, comes from Servier’s $1.8 billion acquisition of Agios Pharmaceuticals’ oncology business. The post Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer appeared first on MedCity News.
pharmaphorum
AUGUST 5, 2024
uniQure sheds two-thirds of its staff as it refocuses around a leaner pipeline headed by Huntington's therapy AMT-130
Pharmaceutical Technology
AUGUST 8, 2024
Novartis has secured US Food and Drug Administration (FDA) accelerated approval for Fabhalta (iptacopan) to treat igAN.
Fierce Pharma
AUGUST 7, 2024
The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. | The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line.
MedCity News
AUGUST 4, 2024
Digital health investors agree that the market is settling into a steady investment pace, as well as returning to reasonable valuations. Only time will tell if this can bolster the tepid rate of exit activity in the sector. The post What Investors Have to Say About Digital Health’s Newly Stable Funding Environment appeared first on MedCity News.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
AUGUST 8, 2024
Roche is said to be considering a sale of cancer data specialist Flatiron Health, just a few years after it bought the company for $1.
Pharmaceutical Technology
AUGUST 8, 2024
Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.
Fierce Pharma
AUGUST 8, 2024
It was 2020 and Maryland biotech Novavax was thinking big. It had a plan to become a COVID vaccine powerhouse, with enough manufacturing capacity to supply the U.S. | As Novavax presented its quarterly earnings, finance chief Jim Kelly said the company was “actively exploring” the sale of its manufacturing facility in the Czech Republic. Novavax purchased the site in May of 2020 for $167 million with the intent of it producing more than 1 billion doses annually there.
MedCity News
AUGUST 4, 2024
Recent financing news includes several companies raising money to advance their research to the clinic. Here’s a look back at funding rounds from companies such as Outpace Bio, GRO Biosciences, and Confo Therapeutics. The post Biotech Financing Roundup: Jade Bio’s Launch, Brenig’s Debut, Confo’s Cash & More appeared first on MedCity News.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
AUGUST 9, 2024
Eli Lilly raises guidance for 2024 by $3 billion on strong growth for tirzepatide in diabetes and obesity and improved supply capacity
Pharmaceutical Technology
AUGUST 8, 2024
Coming in response to a rise in teenage overdoses across the US, the Purdue auto-injector device is designed to be used by anyone.
Fierce Pharma
AUGUST 6, 2024
Servier has expanded its IDH drug armamentarium with the FDA approval for an IDH1/2 dual inhibitor. | Servier's Voranigo, or vorasidenib, is now the first systemic therapy for low-grade IDH-mutant brain cancer.
MedCity News
AUGUST 5, 2024
Bayer reported a Phase 3 test of Kerendia in heart failure led to statistically significant reductions in cardiovascular death and hospitalizations. Detailed results will be presented during the European Society of Cardiology annual meeting in September. The post Bayer Looks to Expand Kerendia’s Label to Heart Failure After Phase 3 Win appeared first on MedCity News.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
pharmaphorum
AUGUST 9, 2024
At the second attempt, the FDA has approved Citius Pharmaceuticals' Lymphir for rare lymphoma CTCL
Salesforce
AUGUST 7, 2024
When a customer isn’t happy, businesses tend to scramble and try to turn things around. However, reactive marketing is like a Band-Aid. It might stop the immediate hurt or frustration, but it doesn’t fix the underlying problem. Eventually, the wound could be reopened. The way around this is to build customer loyalty with an “always on” marketing strategy.
Fierce Pharma
AUGUST 7, 2024
Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. | Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025.
MedCity News
AUGUST 6, 2024
Blue Shield of California members can now access the Blue Zones Challenge App, which guides users to adopt the lifestyle habits of people in blue zones— regions known for longer, healthier lives. The post Blue Shield of California Offers Blue Zones App to Encourage Healthier Living appeared first on MedCity News.
Expert insights. Personalized for you.
105 
Let's personalize your content